CD8A and neoplasm: Anti-tumor efficacy of such aNLG/Oxa(IV)-Lip is enhanced in both SC and orthotopic CT26 tumours due to significantly primed anti-tumor immunity of enhanced intratumoral CD8+ T cell, cytotoxic cytokines and downregulation of immunosuppressive regulatory T cells, which are present in both tumor types.